End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
226.5 CNY | -1.08% | -2.32% | -6.40% |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
- From a short-term investment perspective, the company presents a deteriorated fundamental configuration.
Strengths
- Growth progress expectations are rather promising. Indeed, sales are expected to rise sharply in the coming years.
- Before interest, taxes, depreciation and amortization, the company's margins are particularly high.
- The group's activity appears highly profitable thanks to its outperforming net margins.
- Thanks to a sound financial situation, the firm has significant leeway for investment.
- Analysts covering this company mostly recommend stock overweighting or purchase.
- The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
Weaknesses
- With an expected P/E ratio at 40.68 and 34.69 respectively for both the current and next fiscal years, the company operates with high earnings multiples.
- Based on current prices, the company has particularly high valuation levels.
- In relation to the value of its tangible assets, the company's valuation appears relatively high.
- The valuation of the company is particularly high given the cash flows generated by its activity.
- The firm pays small or no dividend to shareholders. For that reason, it is not a yield company.
- Revenue estimates are regularly revised downwards for the current and coming years.
- The average price target of analysts who are interested in the stock has been significantly revised downwards over the last four months.
- The price targets of analysts who cover the stock differ significantly. This implies difficulties in evaluating the company and its business.
- The company's earnings releases usually do not meet expectations.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Pharmaceuticals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-6.40% | 19.06B | C | ||
+48.28% | 780B | C+ | ||
+41.76% | 627B | B | ||
+20.12% | 334B | B- | ||
+6.92% | 296B | C+ | ||
+17.60% | 244B | B+ | ||
-0.41% | 217B | A+ | ||
+11.54% | 214B | B- | ||
+4.71% | 161B | C+ | ||
-3.47% | 159B | C+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- 600436 Stock
- Ratings Zhangzhou Pientzehuang Pharmaceutical., Ltd